Verve Therapeutics, Inc. (VERV): Price and Financial Metrics
GET POWR RATINGS... FREE!
VERV Stock Price Chart Interactive Chart >
VERV Price/Volume Stats
| Current price | $40.27 | 52-week high | $76.07 |
| Prev. close | $39.94 | 52-week low | $10.70 |
| Day low | $39.31 | Volume | 317,980 |
| Day high | $40.79 | Avg. volume | 825,908 |
| 50-day MA | $29.87 | Dividend yield | N/A |
| 200-day MA | $25.97 | Market Cap | 2.41B |
Verve Therapeutics, Inc. (VERV) Company Bio
Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease.
Latest VERV News From Around the Web
Below are the latest news stories about VERVE THERAPEUTICS INC that investors may wish to consider to help them evaluate VERV as an investment opportunity.
Why Verve Therapeutics Stock Crushed It This WeekVerve Therapeutics (NASDAQ: VERV), a clinical-stage gene-editing company focusing on cardiovascular disease, saw its shares race higher this week by a healthy 17.1%, according to data from S&P Global Intelligence. Verve's shares have been rocketing higher ever since Vertex Pharmaceuticals (NASDAQ: VRTX) entered into a strategic collaboration and license agreement with the biotech for an undisclosed liver disease on July 18, 2022. Vertex reportedly made a $25 million upfront cash payment and agreed to purchase 1,519,756 shares of Verve's common stock at a price of $23.03 per share as part of this liver disease collaboration. |
Verve Therapeutics Posts Updated Preclinical Data For Gene-Editing Therapy In Cardiovascular DiseaseVerve Therapeutics Inc (NASDAQ: VERV) announced new preclinical data supporting the nomination of the company's second product candidate, VERVE-201. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver, a key regulator of cholesterol and triglyceride metabolism. Verve is initially developing VERVE-201 for homozygous familial hypercholesterolemia (HoFH), a rare genetic subtype of atherosclerotic cardiovascular disease (ASCVD) characterized by extremely high blood low-densit |
Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 CongressCAMBRIDGE, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced new preclinical data supporting the nomination of the company’s second product candidate, VERVE-201. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver, a key regulator of cholesterol and triglyceride metabolism, with a precise A-to-G |
Ending Bad Cholesterol With a Single Injection—an Opportunity for Brave InvestorsVerve’s effort to lower patients’ levels of bad cholesterol with a single injection is gradually making clinical progress and would be a significant upgrade from statins and other medicines currently available. |
BMO Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)BMO Capital analyst Kostas Biliouris maintained a Buy rating on Verve Therapeutics (VERV - Research Report) today and set a price target of $62.00. The company's shares opened today at $29.42.According to TipRanks, Biliouris is a 4-star analyst with an average return of 30.8% and a 72.73% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Crispr Therapeutics AG, and Beam Therapeutics.Currently, the analyst consensus on Verve Therapeutics is a Strong Buy with an average price target of $57.00.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $78.00 and a one-year low of $10.70. |
VERV Price Returns
| 1-mo | 42.10% |
| 3-mo | 219.35% |
| 6-mo | 53.29% |
| 1-year | -42.53% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 9.22% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...